Related Experiment Videos
Monosomy-7 in childhood hemopoietic disorders
L Baranger1, A Baruchel, G Leverger
1Unité INSERM U 301 et SDI No. 15954 CNRS, Institute de Génétique Moléculaire, Paris, France.
Leukemia
|May 1, 1990
Summary
Acquired pure monosomy-7 in children leads to poor prognosis in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Bone marrow transplantation offers the best treatment option for these malignant blood disorders.
Area of Science:
- Hematology
- Pediatric Oncology
- Genetics
Background:
- Acquired pure monosomy-7 is a genetic abnormality linked to poor prognosis in pediatric myeloid malignancies.
- This condition is associated with myeloproliferative disorders (MPD), myelodysplastic syndromes (MDS), and acute myeloid leukemias (AML).
Purpose of the Study:
- To report and compare a series of 14 pediatric cases of malignant blood disorders with pure monosomy-7.
- To analyze the clinical characteristics, outcomes, and treatment strategies for these rare pediatric hematologic malignancies.
Main Methods:
- Retrospective analysis of 14 pediatric cases with acquired pure monosomy-7.
- Comparison of patient data with existing literature.
- Analysis of clinical features, age at diagnosis, disease progression, and treatment responses.
Main Results:
- Significant differences in median age were observed between MPD (23 months), MDS (80.5 months), and AML (112 months) groups.
- MPD and RAEB showed a high risk of blastic transformation and resistance to chemotherapy.
- One case of AML achieved 2-year survival in complete remission after autologous bone marrow transplantation (BMT).
Conclusions:
- Pure monosomy-7 in children presents with diverse myeloid disorders and a poor prognosis.
- Bone marrow transplantation (BMT) is suggested as the most effective treatment.
- The disease likely originates from a pluripotent stem cell, affecting multiple myeloid lineages.